Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Reports outline gene therapy study results from University of Zurich, Institute of Virology
August 14th, 2007
Investigators publish new data in the report "HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation. Standard treatment for glioblastoma multiforme and other brain tumors consists of surgical resection followed by combined radio-/chemotherapy. However, radiation resistance of tumor cells limits the success of this treatment, and the tumors invariably recur," scientists writing in the journal Gene Therapy report. "Therefore, the selective inhibition of molecular mediators of radiation resistance may provide therapeutic benefit to the patient. One of these targets is the Rad51 protein, which is a key...
Source: Virus Weekly (2007-08-14)
|
